|
1
|
Brunt EM, Wong VW, Nobili V, Day CP,
Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-Tetri BA
and Rinella ME: Nonalcoholic fatty liver disease. Nat Rev Dis
Primers. 1:150802015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gan C, Yuan Y, Shen H, Gao J, Kong X, Che
Z, Guo Y, Wang H, Dong E and Xiao J: Liver diseases: Epidemiology,
causes, trends and predictions. Signal Transduct Target Ther.
10:332025. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stanley M and Virdee S: Chemical
ubiquitination for decrypting a cellular code. Biochem J.
473:1297–1314. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Satija YK, Bhardwaj A and Das S: A
portrayal of E3 ubiquitin ligases and deubiquitylases in cancer.
Int J Cancer. 133:2759–2768. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schmidt CK, Galanty Y, Sczaniecka-Clift M,
Coates J, Jhujh S, Demir M, Cornwell M, Beli P and Jackson SP:
Systematic E2 screening reveals a UBE2D-RNF138-CtIP axis promoting
DNA repair. Nat Cell Biol. 17:1458–1470. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hrdinka M, Fiil BK, Zucca M, Leske D,
Bagola K, Yabal M, Elliott PR, Damgaard RB, Komander D, Jost PJ and
Gyrd-Hansen M: CYLD Limits Lys63- and Met1-Linked ubiquitin at
receptor complexes to regulate innate immune signaling. Cell Rep.
14:2846–2858. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang Y, Ni S, Xiao B and Jia L: Function,
mechanism and drug discovery of ubiquitin and ubiquitin-like
modification with multiomics profiling for cancer therapy. Acta
Pharm Sin B. 13:4341–4372. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Palazón-Riquelme P, Worboys JD, Green J,
Valera A, Martín-Sánchez F, Pellegrini C, Brough D and
López-Castejón G: USP7 and USP47 deubiquitinases regulate NLRP3
inflammasome activation. EMBO Rep. 19:e447662018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rao Z, Chen X, Wu J, Xiao M, Zhang J, Wang
B, Fang L, Zhang H, Wang X, Yang S and Chen Y: Vitamin D receptor
inhibits NLRP3 activation by impeding its BRCC3-mediated
deubiquitination. Front Immunol. 10:27832019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
When AC, Khalin I, Duering M, Hellal F,
Culmsee C, Vandenabeele P, Plesnila N and Terpolilli NA: RIPK1 or
RIPK3 deletion prevents progressive neuronal cell death and
improves memory function after traumatic brain injury. Acta
Neuropathol Commun. 9:1382021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Keir ME, Butte MJ, Freeman GJ and Sharpe
AH: PD-1 and its ligands in tolerance and immunity. Annu Rev
Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barac YD, Emrich F, Krutzwakd-Josefson E,
Schrepfer S, Sampaio LC, Willerson JT, Robbins RC, Ciechanover A,
Mohr FW, Aravot D and Taylor DA: The ubiquitin-proteasome system: A
potential therapeutic target for heart failure. J Heart Lung
Transplant. 36:708–714. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yuan T, Yan F, Ying M, Cao J, He Q, Zhu H
and Yang B: Inhibition of ubiquitin-specific proteases as a novel
anticancer therapeutic strategy. Front Pharmacol. 9:10802018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Glickman MH and Ciechanover A: The
ubiquitin-proteasome proteolytic pathway: Destruction for the sake
of construction. Physiol Rev. 82:373–428. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang HT, Lumpkin RJ, Tsai RW, Su S, Zhao
X, Xiong Y, Chen J, Mageed N, Donovan KA, Fischer ES and Sellers
WR: Ubiquitin-specific proximity labeling for the identification of
E3 ligase substrates. Nat Chem Biol. 20:1227–1236. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morreale FE and Walden H: Types of
ubiquitin ligases. Cell. 165:248–248.e1. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Asmamaw MD, Liu Y, Zheng YC, Shi XJ and
Liu HM: Skp2 in the ubiquitin-proteasome system: A comprehensive
review. Med Res Rev. 40:1920–1949. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bulatov E, Valiullina A, Sayarova R and
Rizvanov A: Promising new therapeutic targets for regulation of
inflammation and immunity: RING-type E3 ubiquitin ligases. Immunol
Lett. 202:44–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zheng N and Shabek N: Ubiquitin ligases:
Structure, function, and regulation. Annu Rev Biochem. 86:129–157.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Berndsen CE and Wolberger C: New insights
into ubiquitin E3 ligase mechanism. Nat Struct Mol Biol.
21:301–307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deshaies RJ and Joazeiro CA: RING domain
E3 ubiquitin ligases. Annu Rev Biochem. 78:399–434. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Harrigan JA, Jacq X, Martin NM and Jackson
SP: Deubiquitylating enzymes and drug discovery: Emerging
opportunities. Nat Rev Drug Discov. 17:57–78. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee MJ, Lee BH, Hanna J, King RW and
Finley D: Trimming of ubiquitin chains by proteasome-associated
deubiquitinating enzymes. Mol Cell Proteomics. 10:R110.003871.
2011. View Article : Google Scholar
|
|
24
|
Xian Y, Ye J, Tang Y, Zhang N, Peng C,
Huang W and He G: Deubiquitinases as novel therapeutic targets for
diseases. MedComm (2020). 5:e700362024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
O'Donnell MA and Ting AT: NFκB and
ubiquitination: Partners in disarming RIPK1-mediated cell death.
Immunol Res. 54:214–226. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Patrick KL, Bell SL, Weindel CG and Watson
RO: Exploring the ‘multiple-hit hypothesis’ of neurodegenerative
disease: Bacterial infection comes up to bat. Front Cell Infect
Microbiol. 9:1382019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Diamond T, Burn TN, Nishiguchi MA,
Minichino D, Chase J, Chu N, Kreiger PA and Behrens EM: Familial
hemophagocytic lymphohistiocytosis hepatitis is mediated by IFN-γ
in a predominantly hepatic-intrinsic manner. PLoS One.
17:e02695532022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zheng M and Tian Z: Liver-mediated
adaptive immune tolerance. Front Immunol. 10:25252019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheng ML, Nakib D, Perciani CT and
MacParland SA: The immune niche of the liver. Clin Sci (Lond).
135:2445–2466. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shih CC, Liu PY, Chen JH, Liao MH, Hsieh
CM, Ka SM, Wu CC, Lin HT, Wu TH and Chen YC: Macrophage expression
of E3 ubiquitin ligase Grail protects mice from
lipopolysaccharide-induced hyperinflammation and organ injury. PLoS
One. 13:e02082792018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Song G, Liu B, Li Z, Wu H, Wang P, Zhao K,
Jiang G, Zhang L and Gao C: E3 ubiquitin ligase RNF128 promotes
innate antiviral immunity through K63-linked ubiquitination of
TBK1. Nat Immunol. 17:1342–1351. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Komander D, Clague MJ and Urbé S: Breaking
the chains: Structure and function of the deubiquitinases. Nat Rev
Mol Cell Biol. 10:550–563. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kwon YT and Ciechanover A: The ubiquitin
code in the ubiquitin-proteasome system and autophagy. Trends
Biochem Sci. 42:873–886. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Min Y, Kim MJ, Lee S, Chun E and Lee KY:
Inhibition of TRAF6 ubiquitin-ligase activity by PRDX1 leads to
inhibition of NFKB activation and autophagy activation. Autophagy.
14:1347–1358. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou Q, Wang H, Schwartz DM, Stoffels M,
Park YH, Zhang Y, Yang D, Demirkaya E, Takeuchi M, Tsai WL, et al:
Loss-of-function mutations in TNFAIP3 leading to A20
haploinsufficiency cause an early-onset autoinflammatory disease.
Nat Genet. 48:67–73. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Heyninck K, De Valck D, Vanden Berghe W,
Van Criekinge W, Contreras R, Fiers W, Haegeman G and Beyaert R:
The zinc finger protein A20 inhibits TNF-induced
NF-kappaB-dependent gene expression by interfering with an RIP- or
TRAF2-mediated transactivation signal and directly binds to a novel
NF-kappaB-inhibiting protein ABIN. J Cell Biol. 145:1471–1482.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shi CS and Kehrl JH: Traf6 and A20
differentially regulate TLR4-induced autophagy by affecting the
ubiquitination of Beclin 1. Autophagy. 6:986–987. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Korman AJ, Peggs KS and Allison JP:
Checkpoint blockade in cancer immunotherapy. Adv Immunol.
90:297–339. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nurieva RI, Liu X and Dong C: Molecular
mechanisms of T-cell tolerance. Immunol Rev. 241:133–144. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bao M, Hanabuchi S, Facchinetti V, Du Q,
Bover L, Plumas J, Chaperot L, Cao W, Qin J, Sun SC and Liu YJ:
CD2AP/SHIP1 complex positively regulates plasmacytoid dendritic
cell receptor signaling by inhibiting the E3 ubiquitin ligase Cbl.
J Immunol. 189:786–792. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sundqvist A, Bengoechea-Alonso MT, Ye X,
Lukiyanchuk V, Jin J, Harper JW and Ericsson J: Control of lipid
metabolism by phosphorylation-dependent degradation of the SREBP
family of transcription factors by SCF(Fbw7). Cell Metab.
1:379–391. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao GN, Tian ZW, Tian T, Zhu ZP, Zhao WJ,
Tian H, Cheng X, Hu FJ, Hu ML, Tian S, et al: TMBIM1 is an
inhibitor of adipogenesis and its depletion promotes adipocyte
hyperplasia and improves obesity-related metabolic disease. Cell
Metab. 33:1640–1654.e8. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Matheoud D, Sugiura A, Bellemare-Pelletier
A, Laplante A, Rondeau C, Chemali M, Fazel A, Bergeron JJ, Trudeau
LE, Burelle Y, et al: Parkinson's disease-related proteins PINK1
and Parkin repress mitochondrial antigen presentation. Cell.
166:314–327. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Park YJ, Dodantenna N, Kim Y, Kim TH, Lee
HS, Yoo YS, Heo J, Lee JH, Kwon MH, Kang HC, et al:
MARCH5-dependent NLRP3 ubiquitination is required for mitochondrial
NLRP3-NEK7 complex formation and NLRP3 inflammasome activation.
EMBO J. 42:e1134812023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li X, Lin Y, Niu R, Chen S, Pan J, Zhong
Y, Du J, Dong Q, Zhang H, Fang H, et al: Integrated lipidomics and
network pharmacology reveal the AMPK-mediated therapeutic mechanism
of 3,3′-diindolylmethane in hepatic lipid metabolism. Antioxidants
(Basel). 14:10932025. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dowman JK, Tomlinson JW and Newsome PN:
Pathogenesis of non-alcoholic fatty liver disease. QJM. 103:71–83.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tilg H and Moschen AR: Evolution of
inflammation in nonalcoholic fatty liver disease: The multiple
parallel hits hypothesis. Hepatology. 52:1836–1846. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Celebi G, Kesim H, Ozer E and Kutlu O: The
effect of dysfunctional ubiquitin enzymes in the pathogenesis of
most common diseases. Int J Mol Sci. 21:63352020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Karki R, Lee E, Sharma BR, Banoth B and
Kanneganti TD: IRF8 regulates gram-negative bacteria-mediated NLRP3
inflammasome activation and cell death. J Immunol. 204:2514–2522.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Finamore C, De Marino S, Cassiano C,
Napolitano G, Rapacciuolo P, Marchianò S, Biagioli M, Roselli R, Di
Giorgio C, Festa C, et al: BAR502/fibrate conjugates: Synthesis,
biological evaluation and metabolic profile. Front Chem.
12:14258672024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Swanson KV, Deng M and Ting JP: The NLRP3
inflammasome: Molecular activation and regulation to therapeutics.
Nat Rev Immunol. 19:477–489. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Py BF, Kim MS, Vakifahmetoglu-Norberg H
and Yuan J: Deubiquitination of NLRP3 by BRCC3 critically regulates
inflammasome activity. Mol Cell. 49:331–338. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Xu J and Núñez G: The NLRP3 inflammasome:
Activation and regulation. Trends Biochem Sci. 48:331–344. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
He Y, Hara H and Núñez G: Mechanism and
regulation of NLRP3 inflammasome activation. Trends Biochem Sci.
41:1012–1021. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Jo EK, Kim JK, Shin DM and Sasakawa C:
Molecular mechanisms regulating NLRP3 inflammasome activation. Cell
Mol Immunol. 13:148–159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Pinzón-Fernández MV, Saavedra-Torres JS,
López Garzón NA, Pachon-Bueno JS, Tamayo-Giraldo FJ, Rojas Gomez
MC, Arias-Intriago M, Gaibor-Pazmiño A, López-Cortés A and
Izquierdo-Condoy JS: NLRP3 and beyond: Inflammasomes as central
cellular hub and emerging therapeutic target in inflammation and
disease. Front Immunol. 16:16247702025. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yalcinkaya M, Liu W, Thomas LA, Olszewska
M, Xiao T, Abramowicz S, Papapetrou EP, Westerterp M, Wang N, Tabas
I and Tall AR: BRCC3-mediated NLRP3 deubiquitylation promotes
inflammasome activation and atherosclerosis in Tet2 clonal
hematopoiesis. Circulation. 148:1764–1777. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ren G, Zhang X, Xiao Y, Zhang W, Wang Y,
Ma W, Wang X, Song P, Lai L, Chen H, et al: ABRO1 promotes NLRP3
inflammasome activation through regulation of NLRP3
deubiquitination. EMBO J. 38:e1003762019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Gong Z, Li Y, Nie Y, Zhang S, Tang X, Hu
Y, Yang T, Zhu M, Tang W, Su Q, et al: USP50-mediated NLRP3
deubiquitination enhances NLRP3 inflammasome activation to suppress
HCC metastasis. J Pharm Anal. 15:1013802025. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yu J, Li H, Wu Y, Luo M, Chen S, Shen G,
Wei X and Shao B: Inhibition of NLRP3 inflammasome activation by
A20 through modulation of NEK7. Proc Natl Acad Sci USA.
121:e23165511212024. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
D'Arcy MS: Mitophagy in health and
disease: Molecular mechanisms, regulatory pathways, and therapeutic
implications. Apoptosis. 29:1415–1428. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Li YT, Li KY, Tao SS, Wang T, Lu Y, Chen
H, Zhan YQ, Zhao K, Xiang SS, Li JJ, et al: USP13 stabilizes NLRP3
to facilitate inflammasome activation by preventing TRIM31-mediated
NLRP3 ubiquitination and degradation. Sci Adv. 11:eadx38272025.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Liu J, Qian C and Cao X:
Post-translational modification control of innate immunity.
Immunity. 45:15–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Jiang X and Chen ZJ: The role of
ubiquitylation in immune defence and pathogen evasion. Nat Rev
Immunol. 12:35–48. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Min-Wen JC, Jun-Hao ET and Shyh-Chang N:
Stem cell mitochondria during aging. Semin Cell Dev Biol.
52:110–118. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Chen Y, Wang J, An C, Bao S and Zhang C:
The role and research progress of macrophages after heart
transplantation. Heliyon. 10:e338442024. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Mun Y, Kim J, Choi YJ and Lee BH:
cGAS-STING-NF-κB axis mediates rotenone-induced NLRP3 inflammasome
activation through mitochondrial DNA release. Antioxidants (Basel).
14:12762025. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Xian H, Watari K, Sanchez-Lopez E,
Offenberger J, Onyuru J, Sampath H, Ying W, Hoffman HM, Shadel GS
and Karin M: Oxidized DNA fragments exit mitochondria via mPTP- and
VDAC-dependent channels to activate NLRP3 inflammasome and
interferon signaling. Immunity. 55:1370–1385.e8. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Nuzzo D, Galizzi G, Amato A, Terzo S,
Picone P, Cristaldi L, Mulè F and Di Carlo M: Regular intake of
pistachio mitigates the deleterious effects of a high fat-diet in
the brain of obese mice. Antioxidants (Basel). 9:3172020.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Eiyama A and Okamoto K:
PINK1/Parkin-mediated mitophagy in mammalian cells. Curr Opin Cell
Biol. 33:95–101. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
E Y, Lin Y, Yan G, Yang J, Jiao L, Wu R,
Yan Q, Chen Y, Chen Y, Yan X and Li H: Exogenous H2S alleviates
senescence of glomerular mesangial cells through up-regulating
mitophagy by activation of AMPK-ULK1-PINK1-parkin pathway in mice.
Biochim Biophys Acta Mol Cell Res. 1870:1195682023. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yamano K and Youle RJ: PINK1 is degraded
through the N-end rule pathway. Autophagy. 9:1758–1769. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Florentino RM, Animasahun O, Haep N,
Nenwani M, Omoloja K, Altay LN, Achreja A, Morita K, Motomura T,
Diaz-Aragon R, et al: PNPLA3-I148M genetic variant rewires lipid
metabolism to drive programmed cell death in human hepatocytes. JCI
Insight. 10:e1938052025. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Xu X, Pang Y and Fan X: Mitochondria in
oxidative stress, inflammation and aging: From mechanisms to
therapeutic advances. Signal Transduct Target Ther. 10:1902025.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Chen L, Zhang Q, Meng Y, Zhao T, Mu C, Fu
C, Deng C, Feng J, Du S, Liu W, et al: Saturated fatty acids
increase LPI to reduce FUNDC1 dimerization and stability and
mitochondrial function. EMBO Rep. 24:e547312023. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
da Silva Rosa SC, Martens MD, Field JT,
Nguyen L, Kereliuk SM, Hai Y, Chapman D, Diehl-Jones W, Aliani M,
West AR, et al: BNIP3L/Nix-induced mitochondrial fission,
mitophagy, and impaired myocyte glucose uptake are abrogated by
PRKA/PKA phosphorylation. Autophagy. 17:2257–2272. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Shin CH and Choi DS: Essential roles for
the non-canonical IκB kinases in linking inflammation to cancer,
obesity, and diabetes. Cells. 8:1782019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Warnatz K, Salzer U, Rizzi M, Fischer B,
Gutenberger S, Böhm J, Kienzler AK, Pan-Hammarström Q, Hammarström
L, Rakhmanov M, et al: B-cell activating factor receptor deficiency
is associated with an adult-onset antibody deficiency syndrome in
humans. Proc Natl Acad Sci USA. 106:13945–13950. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Grondona P, Bucher P, Schulze-Osthoff K,
Hailfinger S and Schmitt A: NF-κB activation in lymphoid
malignancies: Genetics, signaling, and targeted therapy.
Biomedicines. 6:382018. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Vallabhapurapu S, Matsuzawa A, Zhang W,
Tseng PH, Keats JJ, Wang H, Vignali DA, Bergsagel PL and Karin M:
Nonredundant and complementary functions of TRAF2 and TRAF3 in a
ubiquitination cascade that activates NIK-dependent alternative
NF-kappaB signaling. Nat Immunol. 9:1364–1370. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Xiao G, Harhaj EW and Sun SC:
NF-kappaB-inducing kinase regulates the processing of NF-kappaB2
p100. Mol Cell. 7:401–409. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Zhang B, Hu M, Zhang P, Cao H, Wang Y,
Wang Z and Su T: BAFF promotes regulatory T-cell apoptosis and
blocks cytokine production by activating B cells in primary biliary
cirrhosis. Braz J Med Biol Res. 46:433–439. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Aichele P, Neumann-Haefelin C, Ehl S,
Thimme R, Cathomen T, Boerries M and Hofmann M: Immunopathology
caused by impaired CD8+ T-cell responses. Eur J Immunol.
52:1390–1395. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Moser EK and Oliver PM: Regulation of
autoimmune disease by the E3 ubiquitin ligase Itch. Cell Immunol.
340:1039162019. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Aldaalis A, Bengoechea-Alonso MT and
Ericsson J: The SREBP-dependent regulation of cyclin D1 coordinates
cell proliferation and lipid synthesis. Front Oncol. 12:9423862022.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Shimizu K, Nihira NT, Inuzuka H and Wei W:
Physiological functions of FBW7 in cancer and metabolism. Cell
Signal. 46:15–22. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Han J, Zhong CQ and Zhang DW: Programmed
necrosis: Backup to and competitor with apoptosis in the immune
system. Nat Immunol. 12:1143–1149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Lin X, Chen Q, Huang C and Xu X: CYLD
promotes TNF-α-induced cell necrosis mediated by RIP-1 in human
lung cancer cells. Mediators Inflamm. 2016:15427862016. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Tang J, Zhuang Y, Zhang Y, Hu H, Wang H,
Xu H, Li Y and Tu C: Necroptosis in cancer: Insight from
epigenetic, post-transcriptional and post-translational
modifications. J Hematol Oncol. 18:772025. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Yang Q, Shen X, Luo Y, Li R, Meng X, Xu P,
Liu X, Bian D, Wang J, Shi J and Chen J: ELANE enhances KEAP1
protein stability and reduces NRF2-mediated ferroptosis inhibition
in metabolic dysfunction-associated fatty liver disease. Cell Death
Dis. 16:2662025. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Yu Y, Wang Q, Huang X and Li Z: GA
receptor targeted chitosan oligosaccharide polymer nanoparticles
improve non-alcoholic fatty liver disease by inhibiting
ferroptosis. Int J Biol Macromol. 278((Pt 2)): 1347792024.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
El-Naby SMA, Khedr NF, El-Ashmawy NE and
Ibrahim AO: Proanthocyanidin and mitoglitazone suppress lipogenesis
by targeting ferroptosis in metabolic dysfunction-associated
steatohepatitis. Naunyn Schmiedebergs Arch Pharmacol.
398:15825–15836. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Vucur M, Kondylis V, Broz P and Luedde T:
Regulated necrosis at the crossroads of liver inflammation and
cancer development. Nat Rev Gastroenterol Hepatol. 23:331–354.
2026. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Cao P, Jaeschke H, Ni HM and Ding WX: The
ways to die: Cell death in liver pathophysiology. Semin Liver Dis.
45:397–419. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang
NJ and Harris CC: Mutational hotspot in the p53 gene in human
hepatocellular carcinomas. Nature. 350:427–428. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Brooks CL and Gu W: New insights into p53
activation. Cell Res. 20:614–621. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Iwakuma T and Lozano G: MDM2, an
introduction. Mol Cancer Res. 1:993–1000. 2003.PubMed/NCBI
|
|
98
|
Onel K and Cordon-Cardo C: MDM2 and
prognosis. Mol Cancer Res. 2:1–8. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Chalhoub N and Baker SJ: PTEN and the
PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Tu Y, Wu W, Wu T, Cao Z, Wilkins R, Toh
BH, Cooper ME and Chai Z: Antiproliferative autoantigen CDA1
transcriptionally up-regulates p21(Waf1/Cip1) by activating p53 and
MEK/ERK1/2 MAPK pathways. J Biol Chem. 282:11722–11731. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Khoronenkova SV, Dianova II, Ternette N,
Kessler BM, Parsons JL and Dianov GL: ATM-dependent downregulation
of USP7/HAUSP by PPM1G activates p53 response to DNA damage. Mol
Cell. 45:801–813. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Fan YH, Cheng J, Vasudevan SA, Dou J,
Zhang H, Patel RH, Ma IT, Rojas Y, Zhao Y, Yu Y, et al: USP7
inhibitor P22077 inhibits neuroblastoma growth via inducing
p53-mediated apoptosis. Cell Death Dis. 4:e8672013. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Müller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Zhao M, Wang T, Gleber-Netto FO, Chen Z,
McGrail DJ, Gomez JA, Ju W, Gadhikar MA, Ma W, Shen L, et al:
Mutant p53 gains oncogenic functions through a chromosomal
instability-induced cytosolic DNA response. Nat Commun. 15:1802024.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Zucman-Rossi J, Villanueva A, Nault JC and
Llovet JM: Genetic landscape and biomarkers of hepatocellular
carcinoma. Gastroenterology. 149:1226–1239.e4. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF
and Chen X: β-Catenin signaling in hepatocellular carcinoma. J Clin
Invest. 132:e1545152022. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Jiang J and Struhl G: Regulation of the
Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat
protein Slimb. Nature. 391:493–496. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Jiao S, Wang H, Shi Z, Dong A, Zhang W,
Song X, He F, Wang Y, Zhang Z, Wang W, et al: A peptide mimicking
VGLL4 function acts as a YAP antagonist therapy against gastric
cancer. Cancer Cell. 25:166–180. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Cucu I and Nicolescu MI: A synopsis of
signaling crosstalk of pericytes and endothelial cells in salivary
gland. Dent J (Basel). 12:1442021. View Article : Google Scholar
|
|
110
|
Perugorria MJ, Olaizola P, Labiano I,
Esparza-Baquer A, Marzioni M, Marin JJG, Bujanda L and Banales JM:
Wnt-β-catenin signalling in liver development, health and disease.
Nat Rev Gastroenterol Hepatol. 16:121–136. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Terra ML, Sant'Anna TBF, de Barros JJF and
de Araujo NM: Geographic and viral etiology patterns of TERT
promoter and CTNNB1 exon 3 mutations in hepatocellular carcinoma: A
comprehensive review. Int J Mol Sci. 26:28892025. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Schulze K, Imbeaud S, Letouzé E,
Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C,
Shinde J, Soysouvanh F, et al: Exome sequencing of hepatocellular
carcinomas identifies new mutational signatures and potential
therapeutic targets. Nat Genet. 47:505–511. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Yuan S, Nisar A, Chen C, Dong X, Pan Y, Zi
M, Wang Q, Khan S, Guo Y, Zhang X and He Y: Liver-targeted
degradation of BRD4 reverses hepatic fibrosis and enhances
metabolism in murine models. Theranostics. 15:7270–7290. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Popov N, Schülein C, Jaenicke LA and
Eilers M: Ubiquitylation of the amino terminus of Myc by
SCF(β-TrCP) antagonizes SCF(Fbw7)-mediated turnover. Nat Cell Biol.
12:973–981. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Gan Y, Li X, Han S, Liang Q, Ma X, Rong P,
Wang W and Li W: The cGAS/STING pathway: A novel target for cancer
therapy. Front Immunol. 12:7954012022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Sun L, Wu J, Du F, Chen X and Chen ZJ:
Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates
the type I interferon pathway. Science. 339:786–791. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Zhong B, Zhang L, Lei C, Li Y, Mao AP,
Yang Y, Wang YY, Zhang XL and Shu HB: The ubiquitin ligase RNF5
regulates antiviral responses by mediating degradation of the
adaptor protein MITA. Immunity. 30:397–407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Li Q, Lin L, Tong Y, Liu Y, Mou J, Wang X,
Wang X, Gong Y, Zhao Y, Liu Y, et al: TRIM29 negatively controls
antiviral immune response through targeting STING for degradation.
Cell Discov. 4:132018. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Francisco LM, Sage PT and Sharpe AH: The
PD-1 pathway in tolerance and autoimmunity. Immunol Rev.
236:219–242. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Gou Q, Dong C, Xu H, Khan B, Jin J, Liu Q,
Shi J and Hou Y: PD-L1 degradation pathway and immunotherapy for
cancer. Cell Death Dis. 11:9552020. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Meng X, Liu X, Guo X, Jiang S, Chen T, Hu
Z, Liu H, Bai Y, Xue M, Hu R, et al: FBXO38 mediates PD-1
ubiquitination and regulates anti-tumour immunity of T cells.
Nature. 564:130–135. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu
Y, Chang SS, Lin WC, Hsu JM, Hsu YH, et al: Deubiquitination and
stabilization of PD-L1 by CSN5. Cancer Cell. 30:925–939. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Peng Y, Li T, Liu D, Li W, Zhang Y, Zhao
Y, Jiang X, Liang Y, Chen P, Ma B, et al: Development of cathepsin
B-responsive GalNAc-PROTACs for hepatocyte-targeting protein
degradation. J Med Chem. 69:517–532. 2026.PubMed/NCBI
|
|
124
|
Békés M, Langley DR and Crews CM: PROTAC
targeted protein degraders: The past is prologue. Nat Rev Drug
Discov. 21:181–200. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Bouvier C, Lawrence R, Cavallo F, Xolalpa
W, Jordan A, Hjerpe R and Rodriguez MS: Breaking bad
proteins-discovery approaches and the road to clinic for degraders.
Cells. 13:5782024. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Toure M and Crews CM: Small-molecule
PROTACS: New approaches to protein degradation. Angew Chem Int Ed
Engl. 55:1966–1973. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Spano D and Catara G: Targeting the
ubiquitin-proteasome system and recent advances in cancer therapy.
Cells. 13:292023. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Fuchs O: Treatment of lymphoid and myeloid
malignancies by immunomodulatory drugs. Cardiovasc Hematol Disord
Drug Targets. 19:51–78. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Kim YJ, Lee Y, Shin H, Hwang S, Park J and
Song EJ: Ubiquitin-proteasome system as a target for anticancer
treatment-an update. Arch Pharm Res. 46:573–597. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Scholes NS, Mayor-Ruiz C and Winter GE:
Identification and selectivity profiling of small-molecule
degraders via multi-omics approaches. Cell Chem Biol. 28:1048–1060.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Chamberlain PP and Hamann LG: Development
of targeted protein degradation therapeutics. Nat Chem Biol.
15:937–944. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Garber K: The PROTAC gold rush. Nat
Biotechnol. 40:12–16. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Sakamoto KM, Kim KB, Kumagai A, Mercurio
F, Crews CM and Deshaies RJ: Protacs: chimeric molecules that
target proteins to the Skp1-Cullin-F box complex for ubiquitination
and degradation. Proc Natl Acad Sci USA. 98:8554–8559. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Burslem GM and Crews CM:
Proteolysis-targeting chimeras as therapeutics and tools for
biological discovery. Cell. 181:102–114. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Chirnomas D, Hornberger KR and Crews CM:
Protein degraders enter the clinic-a new approach to cancer
therapy. Nat Rev Clin Oncol. 20:265–278. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Paiva SL and Crews CM: Targeted protein
degradation: Elements of PROTAC design. Curr Opin Chem Biol.
50:111–119. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Yang Z, Zhao J, Xie K, Tang C, Gan C and
Gao J: MASLD development: From molecular pathogenesis toward
therapeutic strategies. Chin Med J (Engl). 138:1807–1824. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Shachaf CM, Kopelman AM, Arvanitis C,
Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B,
Cardiff RD, et al: MYC inactivation uncovers pluripotent
differentiation and tumour dormancy in hepatocellular cancer.
Nature. 431:1112–1117. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Olson DC, Marechal V, Momand J, Chen J,
Romocki C and Levine AJ: Identification and characterization of
multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene.
8:2353–2360. 1993.PubMed/NCBI
|
|
140
|
Lawasut P, Chauhan D, Laubach J, Hayes C,
Fabre C, Maglio M, Mitsiades C, Hideshima T, Anderson KC and
Richardson PG: New proteasome inhibitors in myeloma. Curr Hematol
Malig Rep. 7:258–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
